Analyst Conference Summary

biotechnology

conference date: August 7, 2025
for quarter ending: June 30, 2025 (second quarter, Q2)

Forward-looking statements

Overview: The Phase 2b CD388 trial for flu had positive data.

Basic data (GAAP):

Revenue was $0, flat sequentially from $0, and down from $1 million year-earlier.

Net Income was negative $, down sequentially from negative $23.5 million, and down from negative $ million year-earlier.

EPS (Earnings per Share), diluted, were negative$, down sequentially from negative $1.66, and up from from negative $ year-earlier. Sharecount increased significantly during the year.

Guidance:

none

Conference Highlights:

Jeffrey Stein, CEO, said " "

Preclinical CD388 data was published in March 2025 in Nature Microbiology. Two posters, one on preliminary safety data in the 2b trial and one on Phase 3 planned doses, were presented at the March 2025 ICAR (International Conference on Antiviral Research) conference. CD388 does not depend on the patient's immune system, so may be best in class.

Cash and equivalents ended at $ million, down sequentially from $175 million.

Total operating expenses were $ million, consisting of: R&D $ million, G&A $ million, and a gain from reversal of indirect tax liabilities of $ million. Other expense $ million, interest income $ million.

Q&A selective summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: